Base editors (BEs) have opened new avenues for the treatment of genetic diseases. However, advances in delivery approaches are needed to enable disease targeting of a broad range of tissues and cell types. Adeno-associated virus (AAV) vectors remain one of the most promising delivery vehicles for gene therapies. Currently, most BE/guide combinations and their promoters exceed the packaging limit (∼5 kb) of AAVs. Dual-AAV delivery strategies often require high viral doses that impose safety concerns. In this study, we engineered an adenine base editor (ABE) using a compact Cas9 from Neisseria meningitidis (Nme2Cas9). Compared with the well-characterized Streptococcus pyogenes Cas9-containing ABEs, ABEs using Nme2Cas9 (Nme2-ABE) possess a distinct protospacer adjacent motif (N4CC) and editing window, exhibit fewer off-target effects, and can efficiently install therapeutically relevant mutations in both human and mouse genomes. Importantly, we show that in vivo delivery of Nme2-ABE and its guide RNA by a single AAV vector can efficiently edit mouse genomic loci and revert the disease mutation and phenotype in an adult mouse model of tyrosinemia. We anticipate that Nme2-ABE, by virtue of its compact size and broad targeting range, will enable a range of therapeutic applications with improved safety and efficacy due in part to packaging in a single-vector system.
Get full access to this article
View all access options for this article.
References
1.
LandrumMJ, LeeJM, BensonM, et al.ClinVar: Public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016; 44:D862–D868. DOI: 10.1093/nar/gkv1222.
2.
ReesHA, LiuDR. Base editing: Precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet. 2018; 19:770–788. DOI: 10.1038/s41576-018-0059-1.
3.
GaudelliNM, KomorAC, ReesHA, et al.Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. 2017; 551:464–471. DOI: 10.1038/nature24644.
4.
KomorAC, KimYB, PackerMS, et al.Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016; 533:420–424. DOI: 10.1038/nature24644.
5.
RothganglT, DennisMK, LinPJC, et al.In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat Biotechnol. 2021; 39:949–957. DOI: 10.1038/s41587-021-00933-4.
6.
MusunuruK, ChadwickAC, MizoguchiT, et al.In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021; 593:429–434. DOI: 10.1038/s41586-021-03534-y.
7.
WangL, XueW, ZhangH, et al.Eliminating base-editor-induced genome-wide and transcriptome-wide off-target mutations. Nat Cell Biol. 2021; 23:552–563. DOI: 10.1038/s41556-021-00671-4.
8.
LiuP, LiangS-Q, ZhengC, et al.Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. Nat Commun. 2021; 12:2121. DOI: 10.1038/s41467-021-22295-w.
9.
VilligerL, RothganglT, WitzigmannD, et al.In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA. Nat Biomed Eng. 2021; 5:179–189. DOI: 10.1038/s41551-020-00671-z.
10.
BöckD, RothganglT, VilligerL, et al.In vivo prime editing of a metabolic liver disease in mice. Sci Transl Med. 2022; 14(636):eabl9238. DOI: 10.1126/scitranslmed.abl9238.
11.
KoblanLW, ErdosMR, WilsonC, et al.In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice. Nature. 2021; 589:608–614. DOI: 10.1038/s41586-020-03086-7
12.
RyuS-M, KooT, KimK, et al.Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy. Nat Biotechnol. 2018; 36:536–539. DOI: 10.1038/nbt.4148.
13.
ChemelloF, ChaiAC, LiH, et al.Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. Sci Adv. 2021; 7. [Epub ahead of print]; DOI: 10.1126/sciadv.abg4910.
14.
SuhS, ChoiEH, LeinonenH, et al.Restoration of visual function in adult mice with an inherited retinal disease via adenine base editing. Nat Biomed Eng. 2021; 5:169–178. DOI: 10.1038/s41551-020-00632-6.
15.
ZhiS, ChenY, WuG, et al. Dual-AAV delivering split prime editor system for in vivo genome editing. Mol Ther. 2021. [Epub ahead of print]; DOI: 10.1016/j.ymthe.2021.07.011.
16.
YehW-H, Shubina-OleinikO, LevyJM, et al.In vivo base editing restores sensory transduction and transiently improves auditory function in a mouse model of recessive deafness. Sci Transl Med. 2020; 12:eaay9101.
17.
LimCKW, GapinskeM, BrooksAK, et al.Treatment of a mouse model of ALS by in vivo base editing. Mol Ther. 2020; 28:1177–1189. DOI: 10.1016/j.ymthe.2020.01.005.
18.
LevyJM, YehW-H, PendseN, et al.Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat Biomed Eng. 2020; 4:97–110. DOI: 10.1038/s41551-019-0501-5.
19.
WuZ, YangH, ColosiP. Effect of genome size on AAV vector packaging. Mol Ther. 2010; 18:80–86. DOI: 10.1038/mt.2009.255.
20.
DongJY, FanPD, FrizzellRA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther. 1996; 7:2101–2112. DOI: 10.1089/hum.1996.7.17-2101.
21.
VilligerL, Grisch-ChanHM, LindsayH, et al.Treatment of a metabolic liver disease by in vivo genome base editing in adult mice. Nat Med, 2018; 24:1519–1525. DOI: 10.1038/s41591-018-0209-1.
22.
WinterJ, LuuA, GapinskeM, et al.Targeted exon skipping with AAV-mediated split adenine base editors. Cell Discov. 2019; 5:41. DOI: 10.1038/s41421-019-0109-7.
23.
HindererC, KatzN, BuzaEL, et al.Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther. 2018; 29:285–298. DOI: 10.1089/hum.2018.015.
24.
WilsonJM, FlotteTR. Moving forward after two deaths in a gene therapy trial of myotubular myopathy. Hum Gene Ther. 2020; 31:695–696. DOI: 10.1089/hum.2020.182.
25.
WangL, SmithJ, BretonC, et al.Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol. Nat Biotechnol. 2018; 36:717–725. DOI: 10.1038/nbt.4182.
26.
RanFA, CongL, YanWX, et al.In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015; 520:186–191. DOI: 10.1038/nature14299.
27.
IbraheimR, TaiPWL, MirA, et al.Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo. Nat Commun. 2021; 12:6267. DOI: 10.1038/s41467-021-26518-y.
28.
MaederML, StefanidakisM, WilsonCJ, et al.Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019; 25:229–233. DOI: 10.1038/s41591-018-0327-9.
29.
Nguyen TranMT, Mohd KhalidMKN, WangQ, et al.Engineering domain-inlaid SaCas9 adenine base editors with reduced RNA off-targets and increased on-target DNA editing. Nat Commun. 2020; 11:4871. DOI: 10.1038/s41467-020-18715-y.
30.
EdrakiA, MirA, IbraheimR, et al.A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing. Mol Cell. 2019; 73:714–726.e4. DOI: 10.1016/j.molcel.2018.12.003.
31.
LiuZ, ChenS, JiaY, et al.Efficient and high-fidelity base editor with expanded PAM compatibility for cytidine dinucleotide. Sci China Life Sci. 2021; 64:1355–1367. DOI: 10.1007/s11427-020-1775-2.
32.
XuR, QinR, XieH, et al.Genome editing with type II-C CRISPR-Cas9 systems from Neisseria meningitidis in rice. Plant Biotechnol J. 2022; 20:350–359. DOI: 10.1111/pbi.13716.
33.
HuaK, TaoX, ZhuJ-K. Expanding the base editing scope in rice by using Cas9 variants. Plant Biotechnol J. 2019; 17:499–504. DOI: 10.1111/pbi.12993.
34.
YangL, ZhangX, WangL, et al.Correction to: Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants. Protein Cell. 2019; 10:700. DOI: 10.1007/s13238-019-0631-2.
35.
RichterMF, ZhaoKT, EtonE, et al.Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat Biotechnol. 2020; 38:883–891. DOI: 10.1038/s41587-020-0453-z.
36.
GaudelliNM, LamDK, ReesHA, et al.Directed evolution of adenine base editors with increased activity and therapeutic application. Nat Biotechnol, 2020; 38:892–900. DOI: 10.1038/s41587-020-0491-6.
37.
ReesHA, KomorAC, YehW-H, et al.Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery. Nat Commun. 2017; 8:15790. DOI: 10.1038/ncomms15790.
38.
KimD, LimK, KimS-T, et al.Genome-wide target specificities of CRISPR RNA-guided programmable deaminases. Nat Biotechnol. 2017; 35:475–480. DOI: 10.1038/nbt.3852.
39.
WenJ, CaoT, WuJ, et al.Single AAV-mediated CRISPR-Nme2Cas9 efficiently reduces mutant hTTR expression in a transgenic mouse model of transthyretin amyloidosis. Mol Ther. 2022; 30:164–174. DOI: 10.1016/j.ymthe.2021.05.010.
40.
RauchBJ, SilvisMR, HultquistJF, et al.Inhibition of CRISPR-Cas9 with bacteriophage proteins. Cell. 2017; 168:150–158.e10. DOI: 10.1016/j.cell.2016.12.009.
41.
LeeJ, MirA, EdrakiA, et al.Potent Cas9 inhibition in bacterial and human cells by AcrIIC4 and AcrIIC5 anti-CRISPR proteins. MBio. 2018; 9:e02321-18. DOI: 10.1128/mBio.02321-18.
42.
HwangS, MaxwellKL. Meet the Anti-CRISPRs: Widespread protein inhibitors of CRISPR-Cas Systems. CRISPR J. 2019; 2:23–30. DOI: 10.1089/crispr.2018.0052.
43.
PawlukA, AmraniN, ZhangY, et al.Naturally occurring off-switches for CRISPR-Cas9. Cell. 2016; 167:1829–1838.e9. DOI: 10.1016/j.cell.2016.11.017.
44.
ShinJ, JiangF, LiuJ-J, et al.Disabling Cas9 by an anti-CRISPR DNA mimic. Sci Adv. 2017; 3:e1701620. DOI: 10.1126/sciadv.1701620.
45.
LeeJ, MouH, IbraheimR, et al.Tissue-restricted genome editing in vivo specified by microRNA-repressible anti-CRISPR proteins. RNA. 2019; 25:1421–1431. DOI: 10.1261/rna.071704.119.
46.
HarringtonLB, DoxzenKW, MaE, et al.A broad-spectrum inhibitor of CRISPR-Cas9. Cell. 2017; 170:1224–1233.e15. DOI: 10.1016/j.cell.2017.07.037.
47.
LiangM, SuiT, LiuZ, et al.acriia5 suppresses base editors and reduces their off-target effects. Cells. 2020; 9:1786. DOI: 10.3390/cells9081786.
48.
HoffmannMD, AschenbrennerS, GrosseS, et al.Cell-specific CRISPR–Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins. Nucleic Acids Res. 2019; 47:e75. DOI: 10.1093/nar/gkz271.
49.
BienvenuT, CarriéA, de RouxN, et al.MECP2 mutations account for most cases of typical forms of Rett syndrome. Hum Mol Genet. 2000; 9:1377–1384. DOI: 10.1093/hmg/9.9.1377.
50.
LystMJ, BirdA. Rett syndrome: A complex disorder with simple roots. Nat Rev Genet. 2015; 16:261–275. DOI: 10.1038/nrg3897.
StefanelliG, GandagliaA, CostaM, et al.Brain phosphorylation of MeCP2 at serine 164 is developmentally regulated and globally alters its chromatin association. Sci Rep. 2016; 6:28295. DOI: 10.1038/srep28295.
53.
TanJ, ZhangF, KarcherD, et al.Engineering of high-precision base editors for site-specific single nucleotide replacement. Nat Commun. 2019; 10:439. DOI: 10.1038/s41467-018-08034-8.
54.
ChuSH, PackerM, ReesH, et al.Rationally designed base editors for precise editing of the sickle cell disease mutation. CRISPR J. 2021; 4:169–177. DOI: 10.1089/crispr.2020.0144.
55.
HuangTP, ZhaoKT, MillerSM, et al.Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors. Nat Biotechnol. 2019; 37:626–631. DOI: 10.1038/s41587-019-0134-y.
56.
WangY, ZhouL, LiuN, et al.BE-PIGS: A base-editing tool with deaminases inlaid into Cas9 PI domain significantly expanded the editing scope. Signal Transduct Target Ther. 2019; 4:36. DOI: 10.1038/s41392-019-0072-7.
57.
LiS, YuanB, CaoJ, et al.Docking sites inside Cas9 for adenine base editing diversification and RNA off-target elimination. Nat Commun. 2020; 11:5827. DOI: 10.1038/s41467-020-19730-9.
58.
LiuY, ZhouC, HuangS, et al.A Cas-embedding strategy for minimizing off-target effects of DNA base editors. Nat Commun. 2020; 11:6073. DOI: 10.1038/s41467-020-19690-0.
59.
ChemelloF, WangZ, LiH, et al.Degenerative and regenerative pathways underlying Duchenne muscular dystrophy revealed by single-nucleus RNA sequencing. Proc Natl Acad Sci U S A. 2020; 117:29691–29701. DOI: 10.1073/pnas.2018391117.
60.
AndersonKM, PoosalaP, LindleySR, et al.Targeted cleavage and polyadenylation of RNA by CRISPR-Cas13. bioRxiv. 2019; 531111. DOI: 10.1101/531111.
61.
KoblanLW, DomanJL, WilsonC, et al.Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. Nat Biotechnol. 2018; 36:843–846. DOI: 10.1038/nbt.4172.
62.
PreeceR, GeorgiadisC, GkaziSA, et al.“Mini” U6 Pol III promoter exhibits nucleosome redundancy and supports multiplexed coupling of CRISPR/Cas9 effects. Gene Ther. 2020; 27:451–458. DOI: 10.1038/s41434-020-0142-z.
63.
AponteJL, SegaGA, HauserLJ, et al.Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1. Proc Natl Acad Sci U S A. 2001; 98:641–645. DOI: 10.1073/pnas.98.2.641.
64.
LindstedtS. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992; 340:813–817. DOI: 10.1016/0140-6736(92)92685-9.
65.
YinH, XueW, ChenS, et al.Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. 2014; 32:551–553. DOI: 10.1038/nbt.2884.
66.
YinH, SongC-Q, DorkinJR, et al.Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol. 2016; 34:328–333. DOI: 10.1038/nbt.3471.
67.
SongC-Q, JiangT, RichterM, et al.Adenine base editing in an adult mouse model of tyrosinaemia. Nat Biomed Eng. 2020; 4:125–130. DOI: 10.1038/s41551-019-0357-8.
68.
JiangT, HendersonJM, CooteK, et al.Chemical modifications of adenine base editor mRNA and guide RNA expand its application scope. Nat Commun. 2020; 11:1979. DOI: 10.1038/s41467-020-15892-8.
69.
ShinJH, JungS, RamakrishnaS, et al.In vivo gene correction with targeted sequence substitution through microhomology-mediated end joining. Biochem Biophys Res Commun. 2018; 502:116–122. DOI: 10.1016/j.bbrc.2018.05.130.
70.
JangH, JoDH, ChoCS, et al.Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases. Nat Biomed Eng. 2022; 6:181–194. DOI: 10.1038/s41551-021-00788-9.
71.
ZhangG, BudkerV, WolffJA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther. 1999; 10:1735–1737. DOI: 10.1089/10430349950017734.
72.
PaulkNK, WursthornK, WangZ, et al.Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology. 2010; 51:1200–1208. DOI: 10.1002/hep.23481.
73.
WangM-J, ChenF, LauJTY, et al.Hepatocyte polyploidization and its association with pathophysiological processes. Cell Death Dis. 2017; 8:e2805. DOI: 10.1038/cddis.2017.167.
74.
FryLE, PeddleCF, StevanovicM, et al.Promoter orientation within an AAV-CRISPR vector affects Cas9 expression and gene editing efficiency. CRISPR J. 2020; 3:276–283. DOI: 10.1089/crispr.2020.0021.
75.
AnzaloneAV, KoblanLW, LiuDR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol. 2020; 38:824–844. DOI: 10.1038/s41587-020-0561-9.
76.
NewbyGA, LiuDR. In vivo somatic cell base editing and prime editing. Mol Ther. 2021; 29:3107–3124. DOI: 10.1016/j.ymthe.2021.09.002.
MoralesL, GambhirY, BennettJ, et al.Broader implications of progressive liver dysfunction and lethal sepsis in two boys following systemic high-dose AAV. Mol Ther. 2020; 28:1753–1755. DOI: 10.1016/j.ymthe.2020.07.009.
79.
FlotteTR. Revisiting the “new” inflammatory toxicities of adeno-associated virus vectors. Hum Gene Ther. 2020; 31:398–399. DOI: 10.1089/hum.2020.29117.trf.
80.
WangD, TaiPWL, GaoG. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019; 18:358–378. DOI: 10.1038/s41573-019-0012-9.
81.
WangD, ZhangF, GaoG. CRISPR-based therapeutic genome editing: Strategies and in vivo delivery by AAV vectors. Cell. 2020; 181:136–150. DOI: 10.1016/j.cell.2020.03.023.
82.
IbraheimR, SongC-Q, MirA, et al.All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo. Genome Biol. 2018; 19:137. DOI: 10.1186/s13059-018-1515-0.
83.
KroossSA, DaiZ, SchmidtF, et al.Ex vivo/in vivo gene editing in hepatocytes using “All-in-One” CRISPR-adeno-associated virus vectors with a Self-Linearizing Repair Template. iScience. 2020; 23:100764. DOI: 10.1016/j.isci.2019.100764.
84.
SunW, YangJ, ChengZ, et al.Structures of Neisseria meningitidis Cas9 complexes in catalytically poised and anti-CRISPR-inhibited states. Mol Cell. 2019; 76:938–952.e5. DOI: 10.1016/j.molcel.2019.09.025.
85.
Sena-EstevesM, GaoG. Introducing genes into mammalian cells: Viral vectors. Cold Spring Harb Protoc. 2020; 2020:095513. DOI: 10.1101/pdb.top095513.
86.
AltermanJF, GodinhoBMDC, HasslerMR, et al.A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system. Nat Biotechnol. 2019; 37:884–894. DOI: 10.1038/s41587-019-0205-0.
87.
ClementK, ReesH, CanverMC, et al.CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol. 2019; 37:224–226. DOI: 10.1038/s41587-019-0032-3.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
